Silence Therapeutics Merges with Intradigm
Silence Therapeutics PLC (AIM: SLN) has agreed to merge with Intradigm Corp., a Palo Alto, Calif.-based developer of RNAi therapeutics. Intradigm previously raised around $42 million in VC funding from firms like Alta Partners, Frazier Healthcare, Lilly Ventures, Roche Finance and Astellas Venture. Those firms now hold a 36.6% stake in the combined company, and agreed to invest £5 million in new capital.
16 December 2009•7 mins read
